相关实验视频
Updated: Jun 24, 2025
05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
6.7K
一个基于结构的设计策略,使用Pyrazole-Pyridine衍生物,将TNFα作为抗炎剂:E-Pharmacophore,动态模拟,合成和体外评估
Debojyoti Halder1,2, R S Jeyaprakash2, Balaram Ghosh1
1Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Shamirpet, Hyderabad, 500078, India.
Chemistry & biodiversity
|June 11, 2024
概括
研究人员开发了新型的pyrazole-pyridine化合物,以向瘤缩因子-α (TNFα),这是炎症的关键驱动因素. 有希望的结果表明,这些化合物可能会导致新的抗炎药物.
科学领域:
- 药用化学 医学化学
- 计算化学的计算化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症是对疾病的关键生物反应,往往导致严重的疾病,如炎症性肠道疾病和类风湿性关节炎.
- 瘤亡因子-α (TNFα) 是一种主要的促炎细胞因子,驱动着炎症性疾病的进展.
研究的目的:
- 设计和合成新型的混合化合物,其中包括pyrazole-pyridine部分.
- 通过计算和体外试验方法评估这些化合物的抗炎潜力.
主要方法:
- 虚拟查使用e-pharmacophore假设和TNFα联合连接体.
- 在研究包括对接,DFT分析和分子动态模拟.
- 针对性化合物的合成和抗炎活性的体外评估 (白蛋白变性试验).
主要成果:
- 四种化合物 (Dh1-Dh4) 与铁具有显著的相互作用,与迪克洛芬纳克相比,具有更高的对接得分和更强的稳定性.
- 化合物Dh1在体外表现出118.01μM的白蛋白变化IC50.
- 皮拉-皮里丁支架显示出开发新的抗炎药物的前景.
结论:
- 设计的pyrazole-pyridine混合化合物显示出作为新型抗炎药物的潜力.
- 进一步的体外和体内研究是有必要的,以探索它们的治疗应用.
- 这项研究为开发用于炎症疾病的新疗法开辟了道路.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130